Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Trend
Trending higher.
Left:
||||
Year-over-year research & development expense growth
Latest
12.66%
Near historical average
Average (34q)
12.31%
Historical baseline
Range
High:84.23%
Low:-9.05%
Volatility
757.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 12.66% |
| Q2 2025 | 5.33% |
| Q1 2025 | 14.53% |
| Q4 2024 | 7.53% |
| Q3 2024 | 6.10% |
| Q2 2024 | 9.38% |
| Q1 2024 | 17.03% |
| Q4 2023 | 3.97% |
| Q3 2023 | 7.87% |
| Q2 2023 | 5.65% |
| Q1 2023 | 3.99% |
| Q4 2022 | 15.64% |
| Q3 2022 | -3.06% |
| Q2 2022 | 16.79% |
| Q1 2022 | 14.83% |
| Q4 2021 | 14.01% |
| Q3 2021 | 5.34% |
| Q2 2021 | 16.51% |
| Q1 2021 | 4.48% |
| Q4 2020 | 22.86% |
| Q3 2020 | 8.66% |
| Q2 2020 | -9.05% |
| Q1 2020 | 14.16% |
| Q4 2019 | 2.71% |
| Q3 2019 | 14.95% |
| Q2 2019 | 41.76% |
| Q1 2019 | -5.18% |
| Q4 2018 | 11.11% |
| Q3 2018 | 31.87% |
| Q2 2018 | 10.64% |
| Q1 2018 | 84.23% |
| Q4 2017 | 1.55% |
| Q3 2017 | 21.12% |
| Q2 2017 | 0.87% |
| Q1 2017 | 0.00% |